Down-regulation of transforming growth factor-β receptors I and II is seen in lesional but not non-lesional psoriatic epidermis

British Journal of Dermatology

Volumn 138, Issue 1, 1998, Pages 57-62

  Leivo, T ^a,c   Leivo, I ^b   Kariniemi, A L ^a   Keski Oja, J ^a,b   Virtanen, I ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; SIGNAL TRANSDUCTION;

EID: 0031910532     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02026.x     Document Type: Article

References (38)

1. Fry L. Psoriasis. Br J Dermatol 1988; 119: 445-61.
2. Lowe PM, Lee ML, Jackson CJ et al. The endothelium in psoriasis. Br J Dermatol 1995; 132: 497-505.
3. Granstein RD. Psoriasis: further evidence of a key role for leukocytes. J Clin Invest 1996; 98: 1695-6.
4. Ortonne J-P. Aetiology and pathogenesis of psoriasis. Br J Dermatol 1996; 549: 1-5.
5. Gottlieb SL, Gilleaudeu P, Johnson R et al. Response of psoriasis to a lymphocyte-selective toxin (DAB IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med 1995; 1: 442-7.
6. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996; 98: 1878-87.
7. Carroll JM, Romero MR, Watt FM. Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. Cell 1995; 83: 957-68.
8. Blessing M, Schirmacher P, Kaiser S. Overexpression of bone morphogenetic protein-6 (BMP-6) in the epidermis of transgenic mice: inhibition of stimulation of proliferation depending on the pattern of transgene expression and formation of psoriatic lesions. J Cell Biol 1996; 135: 227-39.
9. Lawrence DA. Transforming growth factor-β: a general review. Eur Cytokine Netw 1996; 7: 363-74.
10. Shipley GD, Pittelkow MR, Wille JJ Jr et al. Reversible inhibition of normal human prokeratinocyte proliferation by type β transforming growth factor-growth inhibitor in serum-free medium. Cancer Res 1986; 46: 2068-71.
11. Reiss M, Sartorelli AC. Regulation of growth and differentiation of human keratinocytes by type β transforming growth factor and epidermal growth factor. Cancer Res 1987; 47: 6705-9.
12. Schmid P, Cox D, McMaster GK, Itin P. In situ hybridization analysis of cytokine, proto-oncogene and tumour suppressor gene expression in psoriasis. Arch Dermatol Res 1993; 285: 334-40.
13. Elder JT, Fisher GJ, Lindquist PB et al. Overexpression of transforming growth factor α in psoriatic epidermis. Science 1989; 243: 811-14.
14. Kane CJ, Knapp AM, Mansbridge JN, Hanawalt PC. Transforming growth factor-β1, localization in normal and psoriatic epidermal keratinocytes in situ. J Cell Physiol 1990; 144: 144-50.
15. Wataya-Kaneda M, Hashimoto K, Kato M et al. Differential localization of TGF-beta-precursor isotypes in psoriatic human skin. J Dermatol Sci 1996; 11: 183-8.
16. Glick A, Kulkarni A, Tennenbaum T et al. Loss of expression of transforming growth factor β in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc Natl Acad Sci USA 1993; 90: 6076-80.
17. 1 in the epidermis of transgenic mice. Proc Natl Acad Sci USA 1993; 90: 5237-41.
18. Massagué J. TGFβ signaling: receptors, transducers, and mad proteins. Cell 1996; 85: 947-50.
19. Wrana JL, Attisano L, Carcamo J et al. TGF-β signals through a heteromeric protein kinase receptor complex. Cell 1992; 71: 1003-14.
20. Wrana JL, Attisano L, Wieser R et al. Mechanism of activation of the TGF-β receptors. Nature 1994; 370: 341-7.
21. Matsuura H, Myokai F, Arata J et al. Expression of type II transforming growth factor-β receptor mRNA in human skin, as revealed by in situ hybridization. J Dermatol Sci 1994; 8: 25-32.
22. Weinstein GD, McGullough JL, Ross P. Cell proliferation in normal epidermis. J Invest Dermatol 1984; 82: 623-8.
23. Taipale J, Keski-Oja J. Hepatocyte growth factor releases epithelial and endothelial cells from growth arrest induced by transforming growth factor-beta-1. J Biol Chem 1996; 271: 4342-8.
24. Taipale J, Miyazono K, Heldin CH, Keski-Oja J. Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol 1994; 124: 171-81.
25. Kariniemi AL, Virtanen I. Altered keratin expression in benign and malignant skin diseases revealed with monoclonal antibodies. Am J Dermatopathol 1989; 11: 202-8.
26. Kariniemi AL, Virtanen I. Dolichos biflorus agglutinin (DBA) reveals a similar basal cell differentiation in normal and psoriatic epidermis. Histochemistry 1989; 93: 129-32.
27. Iseki S, Osumi-Yamashita N, Miyazono K et al. Localization of transforming growth factor-β type I and type II receptors in mouse development. Exp Cell Res 1995; 219: 339-47.
28. Garrigue-Antar L, Munoz-Antonia T, Antonia SJ et al. Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells. Cancer Res 1995; 55: 3982-7.
29. Ito M, Yasui W, Nakayama H et al. Reduced levels of transforming growth factor-beta type I receptor in human gastric carcinomas. Jpn J Cancer Res 1992; 83: 86-92.
30. Raqib R, Lindberg AA, Björk L et al. Down-regulation of gamma interferon, tumor necrosis factor type I, interleukin 1 (IL-1) type I, IL-3, IL-4, and transforming growth factor β type-1 receptors at the local site during the acute phase of Shigella infection. Infect Immun 1495; 63: 3079-87.
31. Zhao Y, Chegini N, Flanders KC. Human fallopian tube expresses transforming growth factor (TGFβ) isoforms, TGFβ type I-III receptor messenger ribonucleic acid and protein, and contains (125I) TGFβ-binding sites. J Clin Endocrinol Metab 1994; 79: 1177-84.
32. Chegini N, Zhao Y, Williams RS, Flanders KC. Human uterine tissue throughout the menstrual cycle expresses transforming growth factor-β1 (TGF-β1), TGF-β2, TGF-β3, and TGF-β type II receptor messenger ribonucleic acid and protein and contains (125I) TGFB 1-binding sites. Endocrinology 1994; 135: 439-49.
33. Spiers EM, Lazarus GS, Lyons-Giordano B. Expression of plasminogen activator enzymes in psoriatic epidermis. J Invest Dermatol 1994; 102: 333-8.
34. Grondahl-Hansen J, Ralfkiaer E, Nielsen LS et al. Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin. J Invest Dermatol 1987; 88: 28-32.
35. Koli K, Keski-Oja J. Vitamin D3 and calcipotriol decrease extracellular plasminogen activator activity in cultured keratinocytes. J Invest Dermatol 1993; 101: 706-12.
36. Kariniemi AL, Lehto VP, Virtanen I. Surface glycoproteins of cultured human keratinocytes from normal and uninvolved psoriatic epidermis. Br J Dermatol 1983; 109: 531-7.
37. Kariniemi AL, Holthöfer H, Miettinen A, Virtanen I. Altered binding of Ulex europaeus I lectin to psoriatic epidermis. Br J Dermatol 1983; 109: 523-9.
38. Koli KM, Arteaga CL. Processing of the transforming growth factor-β type I and II receptors. Biosynthesis and ligand induced regulation. J Biol Chem 1997; 272: 6423-7.